# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Ross Osborn reiterates NeuroPace (NASDAQ:NPCE) with a Overweight and maintains $18 price target.
Wells Fargo analyst Vik Chopra maintains NeuroPace (NASDAQ:NPCE) with a Overweight and lowers the price target from $20 to $15.
NeuroPace continues to expect revenue growth to be primarily driven by increasing sales of its RNS System and higher sales of D...
NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by ...
Morgan Stanley analyst Drew Ranieri maintains NeuroPace (NASDAQ:NPCE) with a Equal-Weight and lowers the price target from $...
Cantor Fitzgerald analyst Ross Osborn reiterates NeuroPace (NASDAQ:NPCE) with a Overweight and maintains $18 price target.
Gross margin to range between 72% and 74%, Total operating expenses to range between $80 million and $84 million, including app...
NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by ...